C
Craig Campbell
Researcher at University of Western Ontario
Publications - 89
Citations - 4031
Craig Campbell is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Population & Duchenne muscular dystrophy. The author has an hindex of 25, co-authored 83 publications receiving 3020 citations. Previous affiliations of Craig Campbell include Boston Children's Hospital & London Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri,Basil T. Darras,Claudia A. Chiriboga,John W. Day,Craig Campbell,Anne M. Connolly,Susan T. Iannaccone,Janbernd Kirschner,Nancy L. Kuntz,Kayoko Saito,Perry B. Shieh,Mar Tulinius,Elena S. Mazzone,Jacqueline Montes,Kathie M. Bishop,Qingqing Yang,Richard Foster,Sarah Gheuens,C. Frank Bennett,Wildon Farwell,Eugene Schneider,Darryl C. De Vivo,Richard S. Finkel +22 more
TL;DR: Among children with later‐onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group.
Journal ArticleDOI
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Catherine L. Bladen,David Salgado,Soledad Monges,Maria E. Foncuberta,Kyriaki Kekou,Konstantina Kosma,Konstantina Kosma,Hugh Dawkins,Leanne Lamont,Anna J. Roy,Teodora Chamova,Velina Guergueltcheva,Sophelia H. S. Chan,Lawrence Korngut,Craig Campbell,Yi Dai,Jen Wang,Nina Barišić,Petr Brabec,Jaana Lahdetie,Maggie C. Walter,Olivia Schreiber-Katz,Veronika Karcagi,Marta Garami,Venkatarman Viswanathan,Farhad Bayat,Filippo Buccella,En Kimura,Zaïda Koeks,Janneke C. van den Bergen,Miriam Rodrigues,Richard Roxburgh,Anna Lusakowska,Anna Kostera-Pruszczyk,Janusz Zimowski,Rosário Santos,Elena Neagu,Svetlana Artemieva,Vedrana Milic Rasic,Dina Vojinovic,Manuel Posada,Clemens Bloetzer,Pierre Yves Jeannet,Franziska Joncourt,Jordi Díaz-Manera,Eduard Gallardo,Ayse Karaduman,Haluk Topaloglu,Rasha El Sherif,Angela Stringer,Andriy V. Shatillo,Ann Martin,Holly L. Peay,Matthew I. Bellgard,Jan Kirschner,Kevin M. Flanigan,Volker Straub,Kate Bushby,Jan J.G.M. Verschuuren,Annemieke Aartsma-Rus,Annemieke Aartsma-Rus,Christophe Béroud,Christophe Béroud,Hanns Lochmüller +63 more
TL;DR: The development and analysis of the TREAT‐NMD DMD Global database is described and mutations were identified that would potentially benefit from novel genetic therapies for DMD including stop codon read‐through therapies and exon skipping therapy.
Journal ArticleDOI
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Katharine Bushby,Richard S. Finkel,Brenda Wong,Richard J. Barohn,Craig Campbell,Giacomo P. Comi,Anne M. Connolly,John W. Day,Kevin M. Flanigan,Nathalie Goemans,Kristi J. Jones,Eugenio Mercuri,Ros Quinlivan,James B. Renfroe,Barry S. Russman,Monique M. Ryan,Mar Tulinius,Thomas Voit,Steven A. Moore,H. Lee Sweeney,Richard T. Abresch,Kim L. Coleman,Michelle Eagle,Julaine Florence,Eduard Gappmaier,Allan M. Glanzman,Erik K Henricson,Jay A. Barth,Gary Elfring,A. Reha,R. Spiegel,Michael W. O'donnell,Stuart W. Peltz,Craig M. McDonald +33 more
TL;DR: As the first investigational new drug targeting the underlying cause of nm‐dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.
Journal ArticleDOI
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald,Craig Campbell,Ricardo Erazo Torricelli,Richard S. Finkel,Richard S. Finkel,Kevin M. Flanigan,Nathalie Goemans,Peter Heydemann,Anna Kamińska,Janbernd Kirschner,Francesco Muntoni,Andrés Nascimento Osorio,Ulrike Schara,Thomas Sejersen,Perry B. Shieh,H. Lee Sweeney,Haluk Topaloglu,Mar Tulinius,Juan J. Vílchez,Thomas Voit,Thomas Voit,Brenda Wong,Gary Elfring,H. Kroger,Xiaohui Luo,Joseph McIntosh,Tuyen Ong,Peter Riebling,Marcio Souza,R. Spiegel,Stuart W. Peltz,Eugenio Mercuri,Lindsay N. Alfano,Michelle Eagle,M. James,Linda Lowes,Anna Mayhew,Elena S. Mazzone,Leslie Nelson,Kristy Rose,Hoda Abdel-Hamid,Susan D. Apkon,Richard J. Barohn,Enrico Bertini,Clemens Bloetzer,Lausanne Canton de Vaud,Russell J. Butterfield,Brigitte Chabrol,Jong-Hee Chae,Daehak-ro Jongno-gu,Giacomi Pietro Comi,Basil T. Darras,Jahannaz Dastgir,Isabelle Desguerre,Raul G Escobar,Erika Finanger,Michela Guglieri,Imelda Hughes,Susan T. Iannaccone,Kristi J. Jones,Peter I. Karachunski,Martin Kudr,Timothy Lotze,Jean K. Mah,Katherine D. Mathews,Yoram Nevo,Julie A. Parsons,Yann Péréon,Alexandra Prufer de Queiroz Campos Araujo,J. Ben Renfroe,Maria Bernadete Dutra de Resende,Monique M. Ryan,Kathryn Selby,Gihan Tennekoon,Giuseppe Vita +74 more
TL;DR: Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity, and there was a significant effect of ataluren in the prespecified subgroup of patients in the intention-to-treat population.
Journal ArticleDOI
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Craig Campbell,Hugh J. McMillan,Jean K. Mah,Mark A. Tarnopolsky,Kathryn Selby,Ty McClure,Dawn Wilson,Matthew L. Sherman,Diana M. Escolar,Kenneth M. Attie +9 more
TL;DR: ACE‐031 use demonstrated trends for pharmacodynamic effects on lean mass, fat mass, BMD, and 6MWT and myostatin inhibition is a promising therapeutic approach for DMD.